TOKYO (Reuters) – Drugmaker Shionogi & Co Ltd has applied for approval to make and sell its oral COVID-19 treatment in Japan, the firm said on Friday.
Known as S-217622, the drug would become the country’s third antiviral pill approved for coronavirus patients, following those developed by Pfizer Inc and Merck & Co.
(Reporting by Rocky Swift; Editing by Clarence Fernandez)
